Intravenous Continuous LMWH Seems to Be Safe Alternative to UFH in VV ECMO Patients
Intravenous Continuous LMWH (enoxaparin) Seems to Be Safe Alternative to UFH in Patients with VV ECMO
1 other identifier
observational
43
1 country
1
Brief Summary
Unfractionated heparin (UFH) is worldwide anticoagulation used and recommended anticoagulation in patients with ECMO support. However, it is accompanied with incidence of bleeding or thrombotic compliaction at about 40-60% and high mortality. Because ECMO produce primary haemosthasis pathology, there is a theory that prophylaxis of thrombosis with low molecular weight heparin (LMWH) e.g. Enoxaparin might be sufficient to prevent ECMO throbosis and thrombosis development in patients. We decided to performed retrospective observation study and analysis of data, from may 2019 until august 2023, in all patients who were put on VV ECMO and to analysis incidence of bleeding, thrombotic and neurologic complications.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 15, 2019
CompletedFirst Submitted
Initial submission to the registry
August 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2023
CompletedFirst Posted
Study publicly available on registry
August 24, 2023
CompletedFebruary 25, 2025
February 1, 2025
4.3 years
August 15, 2023
February 23, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
Incidence of major bleeding complications
Defined by ECMO registry
Daty from may 2019 till august 2023
Incidence of major thrombotic complications
Defined by ECMO registry
Daty from may 2019 till august 2023
Incidence of major neurologic complications
Defined by ECMO registry
Daty from may 2019 till august 2023
Interventions
Eligibility Criteria
patients with respiratory failure put VV ECMO
You may qualify if:
- VV ECMO - use of 2 separate cannulas (jugular and femoral)
- anticoagulation with only intravenous continuous LMWH (Enoxaparin)
- only a period of the first ECMO set running
You may not qualify if:
- pregnancy
- Avalon cannula (one double lumen cannula)
- patients after thoraco-abdominal surgery
- patients after lung transplantation in early postoperative period
- patients after trauma without any type of heparin ,,heparin free" ECMO
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Unoversity Hospital Motol, Department of Anaesthesiology and Intensive Care
Prague, 150 06, Czechia
Related Publications (1)
Durila M, Vajter J, Garaj M, Berousek J, Lischke R, Hlavacek M, Vymazal T. Intravenous enoxaparin guided by anti-Xa in venovenous extracorporeal membrane oxygenation: A retrospective, single-center study. Artif Organs. 2025 Mar;49(3):486-496. doi: 10.1111/aor.14879. Epub 2024 Oct 3.
PMID: 39360891BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Miroslav Durila, prof.
Department of anesthesiology and intensive care medicine, Motol Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- prof.MD. Miroslav Durila, Ph.D., MHA
Study Record Dates
First Submitted
August 15, 2023
First Posted
August 24, 2023
Study Start
May 15, 2019
Primary Completion
August 15, 2023
Study Completion
August 15, 2023
Last Updated
February 25, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share